Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for treatment and/or prevention of pancreatic cancer

A composition and drug technology, applied in the directions of drug combinations, medical preparations containing active ingredients, anti-tumor drugs, etc., can solve the problems of not teaching CAPRIN-1 antigen protein, not recognizing CAPRIN-1 expression, etc.

Active Publication Date: 2014-04-09
TORAY IND INC
View PDF9 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, Patent Document 2 does not recognize that CAPRIN-1 is expressed on pancreatic cancer cells, nor does it teach that CAPRIN-1 can be an antigenic protein for pancreatic cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treatment and/or prevention of pancreatic cancer
  • Pharmaceutical composition for treatment and/or prevention of pancreatic cancer
  • Pharmaceutical composition for treatment and/or prevention of pancreatic cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0198] [Example 1] Identification of pancreatic cancer antigen protein by SEREX method

[0199] (1) Preparation of cDNA library

[0200] Total RNA was extracted from the testis tissue of healthy dogs by the Acid guanidium-Phenol-Chloroform method (Acid guanidium-Phenol-Chloroform method), and using the Oligotex-dT30 mRNA purification kit (manufactured by Takara Shuzo Co., Ltd.), the polymer was purified according to the instructions attached to the kit. A RNA.

[0201] The thus obtained mRNA (5 µg) was used to synthesize a dog testis cDNA phage library. The cDNA phage library was prepared using cDNA Synthesis Kit, ZAP-cDNA Synthesis Kit, and ZAP-cDNA GigapackIII Gold Cloning Kit (manufactured by STRATAGENE), and the library was prepared according to the instructions attached to the kit. The size of the cDNA phage library produced was 7.73×10 5 pfu / ml.

[0202] (2) Screening of cDNA library using serum

[0203] The dog testis cDNA phage library prepared above was used for ...

Embodiment 2

[0211] [Example 2] Preparation of polyclonal antibody against human CAPRIN-1

[0212] Mix 1 mg of human CAPRIN-1 recombinant protein prepared according to Example 3 of WO2010 / 016526 with an equal volume of incomplete Freund's adjuvant (IFA) solution, administer it once every 2 weeks, and subcutaneously administer it to rabbits for 4 Second-rate. Blood is then collected to obtain antiserum containing polyclonal antibodies. This antiserum was further purified using a protein G carrier (manufactured by GE Healthcare Science) to obtain a polyclonal antibody against CAPRIN-1. In addition, an antibody was obtained by purifying the serum of a rabbit to which no antigen was administered using a protein G carrier in the same manner as above, and this obtained antibody was used as a control antibody.

Embodiment 3

[0213] [Example 3] Expression analysis of CAPRIN-1 protein in human pancreatic cancer

[0214] (1) Expression analysis of CAPRIN-1 protein on human pancreatic cancer cells

[0215] Whether or not CAPRIN-1 protein is expressed on the cell surface of four human pancreatic cancer cell lines (Capan-2, MIAPaCa-2, PANC-1, and BxPC-3) whose expression of the CAPRIN-1 gene was confirmed was examined. 10 cells of each human pancreatic cancer cell line whose gene expression was confirmed above were centrifuged in a 1.5 ml microcentrifuge tube. 6 cells. 2 μg (5 μl) of the CAPRIN-1-derived polyclonal antibody prepared in Example 2 was added, suspended in 95 μl of PBS containing 0.1% fetal bovine serum, and left to stand on ice for 1 hour. After washing with PBS, the suspension was suspended in 5 µl of FITC-labeled goat anti-rabbit IgG antibody (manufactured by Santa Cruz) and 95 µl of PBS containing 0.1% fetal bovine serum (FBS), and allowed to stand on ice for 1 hour. After washing wi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a pharmaceutical composition for treatment and / or prevention of pancreatic cancer, which comprises Caprin-1 protein or a fragment thereof having 7 to 12 or more continuous amino acid residues, and an immunologically reactive antibody or a fragment thereof as active ingredients.

Description

technical field [0001] The present invention relates to the novel medical use of an antibody against CAPRIN-1 or a fragment thereof as a therapeutic and / or preventive agent for pancreatic cancer. Background technique [0002] Cancer is the leading cause of all deaths, and the current treatment is mainly surgery, which is performed in combination with radiation therapy and chemotherapy. Despite the development of new surgical methods and the discovery of new anticancer agents in recent years, the status quo is that, except for some cancers, the results of cancer treatment have not been improved. In recent years, with the development of molecular biology and cancer immunology, antibodies specific to cancer, cancer antigens recognized by cytotoxic T cells, and genes encoding cancer antigens have been identified. The expectation of a specific cancer therapy targeting the target (Non-Patent Document 1). [0003] In cancer therapy, in order to reduce side effects, it is necessar...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/395A61K45/00A61P1/18A61P35/00A61P43/00C07K14/47
CPCC07K2317/24A61K2039/5258C07K16/30C07K2317/34A61K2039/505C07K2317/56C07K14/4738A61K39/39558A61K39/0011C07K2317/565C07K2317/732C07K16/303C07K2317/10C07K16/28C07K2317/23A61P1/18A61P35/00A61P43/00A61K39/001102
Inventor 南田佳孝冈野文义斋藤孝则
Owner TORAY IND INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com